Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
Portfolio Pulse from
Ocular Therapeutix has enrolled 311 subjects in its SOL-R trial for AXPAXLI™, targeting wet AMD. This marks significant progress in their second registrational trial.
January 14, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ocular Therapeutix has made significant progress in its SOL-R trial for AXPAXLI™, enrolling 311 subjects. This is a key step in their second registrational trial for wet AMD.
The enrollment of 311 subjects in the SOL-R trial indicates significant progress in Ocular Therapeutix's development of AXPAXLI™ for wet AMD. This milestone is likely to be viewed positively by investors as it demonstrates advancement towards potential regulatory approval and commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90